

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/664,803 |
| Filing Date | September 19, 2003 |
| First Named Inventor | Unchalee Kositprapa |
| Art Unit | 1614 |
| Examiner Name | Not yet assigned |
| Attorney Docket Number | 141-424 |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| MF | CU | WO 99/47125 | 04-12-2005 | Conley et al. | | |
| MF | CV | EP 1 588 708 A1 | 10-26-2005 | Tekeda Pharm. C | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /Marc Fitzgerald/ | Date Considered | 11/06/2006 |
|-----------------------|-------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|------|--------------------------|---------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 10/664,803 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Unchalee Kositprapa |
| | | Art Unit | 1614 |
| | | Examiner Name | Not yet assigned |
| Sheet 2 | of 2 | Attorney Docket Number | 141-424 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| MF | DN | ABDALLA ET AL, Preparation and evaluation of Metformin Hydrochloride Controlled-Release Tablets, STP Pharma 4(1) pp. 15-20, 1988. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Marc Fitzgerald/ | Date Considered | 11/06/2006 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--|---|--------------------------|---------------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | |
| Sheet | 1 | of | 5 |
| | | Application Number | 10/664,803 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Unchalee Kositprapa |
| | | Art Unit | |
| | | Examiner Name | |
| | | Attorney Docket Number | 141-424 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials ¹ | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number - Kind Code ² (if known) | | | |
| MF | AA | us- 3,174,901 | 03-23-1965 | Sterne | |
| | AB | us-3,960,949 | 06-01-1976 | Ahrens et al. | |
| | AC | us-4,166,800 | 09-04-1979 | Fong | |
| | AD | us-4,389,330 | 06-21-1983 | Tice et al. | |
| | AE | us-4,687,777 | 08-18-1987 | Meguro et al. | |
| | AF | us- 4,839,177 | 06-13-1989 | Colombo et al. | |
| | AG | us-4,891,223 | 01-02-1990 | Ambegaonkar et al. | |
| | AH | us-4,968,507 | 11-06-1990 | Zentner et al. | |
| | AI | us-5,294,770 | 03-15-1994 | Riddle et al. | |
| | AJ | us- 5,356,913 | 10-18-1994 | Colca | |
| | AK | us- 5,376,771 | 12-27-1994 | Roy | |
| | AL | us-5,478,852 | 12-26-1995 | Olefsky et al. | |
| | AM | us- 5,602,133 | 02-11-1997 | Antonucci et al. | |
| | AN | us-5,658,474 | 08-19-1997 | Geerke | |
| | AO | us-5,681,584 | 10-28-1997 | Savastano et al. | |
| | AP | us- 5,698,220 | 12-16-1997 | Cardinal et al. | |
| | AQ | us-5,719,188 | 02-17-1998 | Colca | |
| | AR | us- 5,859,037 | 01-12-1999 | Whitcomb | |
| | AS | us- 5,916,584 | 06-29-1999 | O'Donoghue et al. | |
| | AT | us- 5,952,356 | 09-14-1999 | Ikeda et al. | |


| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------------|-----------------------|---|--------------------------------|--|---|----------------|
| Examiner Initials ¹ | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | </ | | | |

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /Marc Fitzgerald/ | Date Considered | 11/06/2006 |
|-----------------------|-------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

| | |
|------------------------|---------------------|
| Application Number | 10/664,803 |
| Filing Date | September 19, 2003 |
| First Named Inventor | Unchalee Kositprapa |
| Art Unit | |
| Examiner Name | |
| Attorney Docket Number | 141-424 |

U.S. PATENT DOCUMENTS

| Examiner Initials ² | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------------------|--------------------------|--|--------------------------------|--|---|
| | | Number - Kind Code ³ (if known) | | | |
| MF | AU | us- 5,955,106 | 09-21-1999 | Moeckel et al. | |
| | AV | us-6,011,049 | 01-04-2000 | Whitcomb | |
| | AW | us-6,031,004 | 02-29-2000 | Timmins et al. | |
| | AX | us-6,099,859 | 08-08-2000 | Cheng et al. | |
| | AY | us-6,153,632 | 11-28-2000 | Rieveley | |
| | AZ | us- 6,191,162 | 02-20-2001 | Byrd et al. | |
| | BA | us- 6,248,363 | 06-19-2001 | Patel et al. | |
| | BB | us- 6,291,495 | 09-18-2001 | Rieveley | |
| | BC | us- 6,296,874 | 10-02-2001 | Cutie et al. | |
| | BD | us- 6,329,403 | 12-11-2001 | Odaka et al. | |
| | BE | us- 6,383,471 | 05-07-2002 | Chen et al. | |
| | BF | us-6,403,121 | 06-11-2002 | Adjei et al. | |
| | BG | us- 2002/0071866 | 06-13-2002 | Geerke | |
| | BH | us-6,451,342 | 09-17-2002 | Adjei et al. | |
| | BI | us-6,475,521 | 11-05-2002 | Timmins et al. | |
| | BJ | us- 6,524,621 | 02-25-2003 | Adjei et al. | |
| | BK | us-2003/0113371 | 06-19-2003 | Dhawan et al. | |
| | BL | us- 2003/0118647 | 06-26-2003 | Seth | |
| | BM | us- 2003/0118649 | 06-26-2003 | Gao et al. | |
| MF | BN | us- 6,599,284 | 07-29-2003 | Faour | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials ² | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------------------|--------------------------|---|--------------------------------|--|---|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| MF | CA | WO 96/09823 | 04-04-1996 | Luo et al. | | |
| | CB | WO 98/11879 | 03-26-1998 | Shell et al. | | |
| | CC | WO 98/55107 | 12-10-1998 | Shell et al. | | |
| | CD | WO 99/47128 | 09-23-1999 | Timmins et al. | | |
| | CE | WO 99/55320 | 11-04-1999 | Nishii et al. | | |
| | CF | WO 00/28989 | 05-25-2000 | Lewis et al. | | |
| | CG | WO 00/72827 | 12-07-2000 | Straub et al. | | |
| | CH | WO 01/35940 | 05-25-2001 | Lewis et al. | | |
| | CI | WO 01/35941 | 05-25-2001 | Lilliot et al. | | |
| MF | CJ | WO 01/82875 | 11-08-2001 | Cutie et al. | | |

Examiner
Signature

/Marc Fitzgerald/

Date
Considered

11/06/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

| | | | |
|---|------|----------------------------|---------------------|
| Substitute for form 1449B/PTO | | Completion if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/664,803 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Unchalee Kositprapa |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 4 | of 5 | Attorney Docket Number | 141-424 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| MF | DA | P. Karttunen et al., International Journal of Clinical Pharmacology, Therapy and Toxicology, "The pharmacokinetics of metformin: a comparison of the properties of a rapid release and a sustained-release preparation" Vol. 21, No. 1 - 1983, pp. 31-36. | |
| | DB | P.J. Pentikainen, International Journal of Clinical Pharmacology, Therapy and Toxicology, "Bioavailability of metformin. Comparison of solution, rapidly dissolving-tablet, and three sustained-release-products", Vol. 24, No. 4 - 1986, pp. 213-220. | |
| | DC | Finnish Monograph of the Diformin®, Retard tablet, with English translation | |
| | DD | O.J. Lucis, MD, Ph.D., MSC, Canada Medical Association J. Pharmacologic Update "The status of metformin in Canada" Vol. 128, January 1, 1983, pgs. 24-26. | |
| | DE | G. Belcher and D.R. Matthews Experiment and Clinical Endocrinology & Diabetes, "Safety and tolerability of pioglitazone" Suppl. 2 (2000) pgs. 267-273. | |
| | DF | Daniel Einhorn, MD et al., Clinical Therapeutics "Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study", Vol. 22, No. 12, 2000 pgs. 1395-1413. | |
| | DG | National Institute for Clinical Excellence Technology Appraisal Guidance - No. 21, "Guidance on the Use of Pioglitazone for Type 2 Diabetes Mellitus" March 2001, pgs. 1-13. | |
| MF | DH | The Pharmaceutical Journal, Vol. 265, No. 7122, p. 710 November 11, 2000 Clinical (abstract only). | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Marc Fitzgerald/ | Date Considered | 11/06/2006 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|---------------------|
| Substitute for form 1449B/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/664,803 |
| | | Filing Date | September 19, 2003 |
| | | First Named Inventor | Unchalee Kositprapa |
| | | Group Art Unit | |
| | | Examiner Name | |
| Sheet 5 of 5 | Attorney Docket Number | 141-424 | |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|--|----------------|
| Examiner Initials ¹ | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| MF | DI | Product Labeling for Glucophage® XR (July 2002). | |
| | DJ | ADA Professional Section Member Supplement 047 and 0503-506 (Poster) p. A110; A117 | |
| | DK | Website www.findarticles.com, Clinician Reviews, "Insulin-Sensitizing Diabetes Agent" September 1999. | |
| | DL | ACTOS® product label, Physician's Desk Reference, 55th Edition, pp. 3171-3175 | |
| | DM | Rote Liste No. 11081 the Medicament Mediabet of MEDICE, Chem.-Pharm. Fabrik Pütter GmbH & Co. KG, Kuhlweg 37-39 Iserlohn/Germany, Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH, 1993. | |
| MF | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Marc Fitzgerald/ | Date Considered | 11/06/2006 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.